vip
demonstr
effect
host
anim
model
prevent
infect
sever
pathogen
especi
commonli
afflict
travel
see
tabl
includ
influenza
viru
malaria
plasmodium
falciparum
hepat
c
viru
respiratori
synciti
viru
bacillu
anthraci
dengu
viru
chickungunya
viru
addit
protect
confer
system
neutral
antibodi
protect
infect
influenza
viru
also
demonstr
follow
intranas
administr
vector
local
antibodi
product
far
extens
promis
explor
vip
infecti
diseas
hiv
initi
studi
demonstr
potenti
vip
recombin
adenoassoci
viru
raav
vector
use
dualpromot
system
gener
light
heavi
chain
one
earli
broadli
neutral
antibodi
describ
hiv
raav
inject
quadricep
muscl
immunodefici
mice
biolog
activ
antibodi
found
sera
month
studi
provid
first
evid
raav
vector
could
transfer
antibodi
gene
muscl
muscl
tissu
suitabl
platform
produc
distribut
antibodi
throughout
circul
followon
studi
use
nativ
macaqu
siv
fab
molecul
immunoadhesin
chimer
antibodylik
molecul
combin
function
domain
bind
protein
immunoglobulin
constant
domain
consid
superior
singl
chain
scfv
whole
antibodi
igg
molecul
respect
achiev
steadyst
serum
concentr
six
nine
rhesu
macaqu
complet
protect
intraven
challeng
virul
siv
still
stabl
immunoadhesin
level
year
inject
three
subject
protect
found
develop
immun
respons
immunoadhesin
week
inject
anoth
group
use
raav
vector
inject
quadricep
muscl
human
mous
express
array
broadli
neutral
antibodi
though
serum
level
low
provid
protect
intraven
challeng
hiv
achiev
concentr
high
least
month
followedup
studi
optim
broadli
neutral
antibodi
although
muscl
chosen
platform
express
secret
isotyp
antibodi
found
effect
reach
vagin
mucosa
anim
receiv
vip
express
modifi
antibodi
concentr
nearli
serum
vagin
wash
fluid
complet
resist
repetit
intravagin
challeng
heterosexu
transmit
founder
hiv
strain
saunder
et
al
use
raav
serotyp
vector
produc
full
length
igg
simian
form
broadli
neutral
antibodi
macaqu
protect
simianhuman
immunodefici
viru
shiv
infect
week
treatment
shiv
chimer
virus
construct
express
hiv
envelop
glycoprotein
use
vaccin
experi
evalu
neutral
antibodi
antibodi
reach
level
week
immun
suppress
cyclosporin
need
sustain
express
due
develop
antiidiotyp
antibodi
approach
prevent
hiv
enhanc
fuse
immunoadhesin
form
small
sulfopeptid
carboxyterminu
potent
best
broadli
neutral
antiodi
bind
avidli
envelop
glycoprotein
rhesu
macaqu
express
fulli
function
rhesu
week
inject
self
complimentari
serotyp
aav
vector
complet
protect
multipl
challeng
simianhuman
immunodefici
viru
note
rhesu
also
markedli
less
immunogen
rhesu
form
four
wellcharacter
broadli
neutral
antibodi
addit
diseas
prevent
note
studi
also
demonstr
applic
vip
effect
treatment
previouslyinfect
anim
use
human
mice
horwitz
et
al
demonstr
follow
initi
treatment
antiretrovir
therapi
art
singl
inject
adenoassoci
viru
direct
express
broadli
neutral
antibodi
produc
durabl
virem
control
art
stop
first
human
trial
use
vip
approach
start
januari
phase
random
blind
doseescal
studi
vector
code
potent
broadli
neutral
antibodi
high
risk
healthi
adult
male
clinicaltrialsgov
number
anoth
studi
evalu
use
vip
hivposit
subject
schedul
get
underway
soon
mani
option
exist
vector
transgen
host
tissu
distinct
advantag
limit
nake
plasmid
dna
rel
easi
use
elicit
signific
immunogen
potenti
inexpens
largescal
product
recent
advanc
mechan
deliveri
optim
plasmid
electropor
condit
improv
concentr
durat
antibodi
product
yet
prove
potent
viral
vector
viral
vector
offer
advantag
effici
rapid
deliveri
transgen
host
cell
potenti
integr
host
genom
allow
sustain
express
life
cycl
viru
consist
attach
penetr
uncoat
replic
gene
express
assembl
bud
replic
gene
express
typic
take
place
nucleu
viral
genom
persist
episom
integr
host
genom
ie
proviru
vector
persist
episom
provid
sustain
transgen
express
postmitot
tissu
sinc
alter
host
genom
may
lost
cell
divid
vector
integr
host
genom
may
provid
lifelong
transgen
express
divid
cell
could
also
lead
insert
mutagenesi
result
apoptosi
malign
transform
adenovir
vector
produc
rapid
transient
gene
express
could
ideal
respond
diseas
outbreak
would
limit
long
term
protect
adenoviru
serotyp
success
transduc
protect
antibodi
respiratori
syncyti
viru
rsv
influenza
viru
iav
bacillu
anthraci
genom
easi
engin
remain
episom
signific
preexist
immun
estim
adult
popul
worldwid
even
higher
subsaharan
arica
decreas
abil
transfer
transgen
addit
result
system
cytokin
releas
creat
sepsi
present
signific
tissu
tropism
liver
deliv
intraven
altern
adenovir
vector
research
lentivr
vector
better
suit
long
term
express
sinc
typic
integr
genom
transduc
divid
nondivid
cell
success
util
transduc
hematopoiet
stem
cell
produc
broadli
neutral
antibodi
hiv
mous
model
howev
integr
host
genom
concern
mutagenesi
newer
gener
lentivir
vector
contain
delet
longtermin
repeat
ltr
selfinactiv
sin
ltr
leav
replic
incompet
make
much
safer
question
fulli
answer
although
viral
vector
explor
raav
vector
current
favor
vehicl
deliv
antiodi
gene
host
tissu
due
effici
gene
transfer
contrast
viral
vector
adenoviru
raav
associ
human
diseas
stimul
signfic
immunolog
reaction
therefor
abl
induc
longterm
express
nonselfprotein
engin
consist
antibodi
gene
express
cassett
flank
aav
itr
invert
termin
repeat
part
aav
genom
present
raav
vector
requir
raav
vector
genom
replic
packag
despit
relativley
small
packag
capac
kb
heavi
lightchain
antibodi
gene
incorpor
singl
vector
either
use
promot
gene
cassett
singl
promot
express
heavi
light
chain
separ
footandmouth
diseas
viru
peptid
studi
date
target
skelet
muscl
platform
transfect
antibodi
product
muscl
offer
signific
advantag
easili
access
local
vector
administr
muscl
group
remov
event
mutagenesi
autoimmun
without
function
consequ
howev
muscl
certain
disadvantag
well
tissu
normal
produc
circul
protein
therefor
may
effici
also
contain
antigenpres
dendrit
cell
could
induc
immun
respons
might
elimin
transduc
cell
induc
autoimmun
addit
remov
muscl
tissu
would
like
signific
effect
subject
lifestyl
event
potenti
unexpect
vipinduc
patholog
platform
consid
exampl
author
suggest
liver
altern
site
unlik
muscl
design
secret
circul
protein
also
thought
less
immunogen
howev
transduct
would
requir
system
administr
vector
would
simpl
mean
elimin
express
event
complic
anoth
potenti
site
could
salivari
gland
wellknow
salivari
gland
secret
protein
oral
caviti
may
less
well
appreci
also
use
platform
deliv
therapeut
protein
includ
igg
fc
fragment
host
protein
system
circul
transgen
deliv
salivari
gland
tend
favor
sort
either
saliva
blood
though
current
challeng
predict
direct
particular
protein
sort
major
pair
salivari
gland
also
easili
access
parotid
gland
encapsul
minim
vector
spillag
gener
circul
futhermor
event
complic
transfect
gland
could
remov
without
creat
major
disabl
safeti
concern
associ
vip
includ
genotox
event
typic
associ
viral
vector
mediat
gene
therapi
inflamm
random
insert
disrupt
normal
gene
activ
protooncogen
insert
mutagenesi
mani
factor
affect
likelihood
develop
genotox
event
includ
vector
target
insert
site
transgen
target
cell
type
host
factor
includ
age
underli
diseas
risk
genotox
carcinogen
potenti
decreas
select
promot
integr
site
use
novel
techniqu
cluster
regularli
interspac
short
palindrom
repeat
crispr
rnaguid
geneedit
platform
allow
cut
dna
specifi
gene
much
work
need
done
better
character
safeti
efficaci
method
purpos
vip
produc
monoclon
antibodi
possibl
produc
paraproteinemia
similar
caus
multipl
myeloma
hematolog
malign
primari
amyloidosi
monoclon
gammopathi
undertermin
signific
mgu
concern
benign
mgu
increasingli
recogn
patholog
associ
includ
nephropathi
secondari
monoclon
gammopathi
renal
signific
mgr
neuropathi
oculopathi
dermopathi
well
possibl
associ
autoimmun
coagulopathi
epidemiolog
associ
earli
mortal
varieti
appar
unrel
caus
condit
could
result
monoclon
gammopathi
produc
vip
howev
note
mgu
common
occur
popul
older
year
old
associ
remain
either
unclear
uncommon
howev
potenti
autoimmun
particular
concern
possibl
monoclon
antibodi
could
interact
selfantigen
either
stimul
autoimmun
antibodi
interact
selfantigen
neutral
intend
effect
monoclon
antibodi
vector
immunoprophylaxi
demonstr
great
promis
varieti
preclin
studi
potenti
adjunct
vaccin
patient
abl
respond
effect
immun
altern
vaccin
infecti
diseas
effect
cover
current
vaccin
rapid
identif
specif
neutral
antibodi
like
increas
potenti
method
one
could
imagin
use
vip
adjunct
vaccin
influenza
elderli
immunocompromis
hiv
protect
high
risk
popul
part
ring
vaccin
strategi
outbreak
diseas
ebola
mani
import
question
remain
includ
abil
produc
equal
effect
clinic
result
human
trial
durat
respons
potenti
sideeffect
mutagenesi
site
transfect
common
concern
develop
immun
respons
transgen
product
offtarget
bind
antibodi
like
scenario
either
could
result
decreas
efficaci
procedur
signific
autoimmun
reaction
question
also
remain
concern
best
vector
optim
tissu
site
transfect
despit
question
concern
advantag
offer
set
rang
chronic
protect
age
immunocompromis
rapid
protect
earli
respond
event
bioterror
emerg
infect
event
signific
intrigu
preclin
clinic
studi
certainli
warrant
